Large Analysis Supports Thrombolysis for Stroke — Physician’s First Watch

Medical News |
August 6, 2014

Large Analysis Supports Thrombolysis for Stroke

By Larry Husten

Edited by Lorenzo Di Francesco, MD, FACP, FHM

A Lancet meta-analysis offers evidence that the use of thrombolysis should be more aggressively pursued across various subgroups of patients with ischemic stroke.

Researchers examined data from nine randomized trials testing alteplase against placebo or open control in nearly 6800 patients. Thrombolysis was more likely to lead to a good stroke outcome, defined as no significant disability at 3 to 6 months, in patients treated within 4.5 hours. In particular, for treatment within 3 hours, 33% of alteplase recipients versus 23% of controls had good outcomes.

The chief disadvantage to thrombolysis was an early increase in intracranial hemorrhage (ICH), with 2.7% of alteplase recipients and 0.4% of controls having a fatal ICH by day 7. This resulted in a significant increase in early mortality, which was no longer significant at day 90.

Benefit and risk did not vary based on age or stroke severity. Despite the early increase in mortality, the authors concluded that thrombolysis was associated with an average absolute increase in disability-free survival of approximately 10% among patients treated within 3 hours and 5% for those treated between 3 and 4.5 hours.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
Last load event
Format: 2016-08-31 14:23:08
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.